RE: RNS NXP002 Update - excellent27 Mar 2023 08:15
"All parties are delighted with the results from this study, which are as good as we could have hoped for and are the first results from what is the most advanced iteration of this 'close to patient' IPF disease model to date. The reduced variability in the resulting data allows us to have high confidence in both NXP002's anti-fibrotic activity alone, but also in the added anti-fibrotic performance it can deliver on top of existing standards of care.